Cargando…

ACEI/ARB and beta-blocker therapies for preventing cardiotoxicity of antineoplastic agents in breast cancer: a systematic review and meta-analysis

Anthracyclines and trastuzumab are widely used to treat breast cancer but increase the risk of cardiomyopathy and heart failure. With the use of trastuzumab and anthracycline-containing medications, this study intends to evaluate the effectiveness and security of current treatments against cardiotox...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gao, Yu, Wang, Ruiting, Jiang, Jinchi, Hu, Yueyao, Li, Haijing, Wang, Yong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10575808/ https://www.ncbi.nlm.nih.gov/pubmed/37414918 http://dx.doi.org/10.1007/s10741-023-10328-z

Ejemplares similares

Can ACEI/ARB prevent the cardiotoxicity caused by chemotherapy in early-stage breast cancer?—a meta-analysis of randomized controlled trials
por: Dong, Haoran, et al.
Publicado: (2020)

ACEI and ARB Lower the Incidence of End-Stage Renal Disease among Patients with Diabetic Nephropathy: A Meta-analysis
por: Deng, Xiaojuan, et al.
Publicado: (2022)

Effects of ACEI and ARB on COVID-19 patients: A meta-analysis
por: Xue, Yang, et al.
Publicado: (2020)

Long-term clinical outcome between beta-blocker with ACEI or ARB in patients with NSTEMI who underwent PCI with drug-eluting stents
por: Kim, Yong Hoon, et al.
Publicado: (2019)

Angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARBs) may be safe for COVID-19 patients
por: Wang, Wenjun, et al.
Publicado: (2021)

ACEIs and ARBs and Their Correlation with COVID-19: A Review
por: Yehualashet, Awgichew Shewasinad, et al.
Publicado: (2020)

The role of ACEIs/ARBs in COVID-19: Friend or foe?
por: Zhou, Zhe, et al.
Publicado: (2020)

Withdrawal of ACEIs or ARBs in hospitalised patients with COVID-19
Publicado: (2021)

ACEI inhibitors and ARBs do not increase severity of COVID-19
Publicado: (2020)

Outcomes in Patients with COVID-19 Infection Taking ACEI/ARB
por: Rico-Mesa, Juan Simon, et al.
Publicado: (2020)

Is there a difference in the effect between the ACEI and ARB on COVID‐19?
por: Chen, Jie, et al.
Publicado: (2020)

ACEI/ARB Drug Therapy in COVID-19 Patients: Yes Or No?
por: Gong, Jin, et al.
Publicado: (2021)

Personalized prescription of ACEI/ARBs for hypertensive COVID-19 patients
por: Bertsimas, Dimitris, et al.
Publicado: (2021)

ARB might be superior to ACEI for treatment of hypertensive COVID‐19 patients
por: Zhao, Hong‐Jin, et al.
Publicado: (2021)

Text mining online disinformation about antihypertensive agents ACEI/ARB and COVID-19 on Sina Weibo
por: Wang, Chunli, et al.
Publicado: (2023)

MicroRNA Expression Profile in CAD Patients and the Impact of ACEI/ARB
por: Weber, Martina, et al.
Publicado: (2011)

Would ACEIs/ARBs be beneficial for COVID-19 patients without hypertension?
por: Huang, Ying, et al.
Publicado: (2020)

Review of evidence on using ACEi and ARBs in patients with hypertension and COVID-19
por: Khan, Sikandar Hayat, et al.
Publicado: (2020)

Antihypertensive treatment with ACEI/ARB of patients with COVID-19 complicated by hypertension
por: Li, Gang, et al.
Publicado: (2020)

Safety of ACEi and ARB in COVID‐19 management: A retrospective analysis
por: Kumar, Sabina, et al.
Publicado: (2022)

Centrally acting ACE inhibitor (cACEi) and angiotensin receptor blocker (cARB) use and cognitive dysfunction in patients with SLE
por: Dobrowolski, Chrisanna, et al.
Publicado: (2023)

ARNI versus ACEI/ARB in Reducing Cardiovascular Outcomes after Myocardial Infarction
por: She, Jianqing, et al.
Publicado: (2021)

Pentoxifylline plus ACEIs/ARBs for proteinuria and kidney function in chronic kidney disease: a meta-analysis
por: Liu, Dong, et al.
Publicado: (2017)

The clinical efficacy of fluticasone propionate combined with ACEI/ARB in the treatment of immunoglobulin A nephropathy
por: Sun, Liping, et al.
Publicado: (2023)

Cardiovascular and cerebrovascular outcomes in elderly hypertensive patients treated with either ARB or ACEI
por: Ma, Cong, et al.
Publicado: (2012)

COVID-19, ACEI/ARBs, and Gastrointestinal Symptoms: The Jury Is Still Out on the Association
por: Parigi, Tommaso Lorenzo, et al.
Publicado: (2021)

ACEIs, ARBs, ibuprofen originally linked to COVID-19: the other side of the mirror
por: Kelleni, Mina T.
Publicado: (2020)

Association of ACEi/ARB Use and Clinical Outcomes of COVID-19 Patients With Hypertension
por: Ma, Jing, et al.
Publicado: (2021)

Accepting Medication Therapy Management Recommendations to Add ACEIs or ARBs in Diabetes Care
por: Hurwitz, Jason T., et al.
Publicado: (2016)

Comparing clinical outcomes of ARB and ACEi in patients hospitalized for acute COVID-19
por: Hamada, Seiji, et al.
Publicado: (2023)

Effects of ACEIs Versus ARBs on Proteinuria or Albuminuria in Primary Hypertension: A Meta-Analysis of Randomized Trials
por: Xu, Rui, et al.
Publicado: (2015)

Systematic review and meta-analysis of the clinical outcomes of ACEI/ARB in East-Asian patients with COVID-19
por: Huang, Nancy Xurui, et al.
Publicado: (2023)

Effects of ACEI/ARB in hypertensive patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled studies
por: Hao, Guang, et al.
Publicado: (2014)

Antihypertensive Therapy by ACEI/ARB Is Associated With Intestinal Flora Alterations and Metabolomic Profiles in Hypertensive Patients
por: Dong, Ying, et al.
Publicado: (2022)

SARS-CoV-2 downregulation of ACE2 and pleiotropic effects of ACEIs/ARBs
por: Ciulla, Michele M.
Publicado: (2020)

Mortality and Severity in COVID-19 Patients on ACEIs and ARBs—A Systematic Review, Meta-Analysis, and Meta-Regression Analysis
por: Singh, Romil, et al.
Publicado: (2022)

ACEI/ARB use and risk of infection or severity or mortality of COVID-19: A systematic review and meta-analysis
por: Zhang, Xue, et al.
Publicado: (2020)

Effect of sacubitril/valsartan and ACEI/ARB on glycaemia and the development of diabetes: a systematic review and meta-analysis of randomised controlled trials
por: Wang, Ruxin, et al.
Publicado: (2022)

Angiotensin-Converting Enzyme Inhibitors (ACEIs) and Angiotensin-Receptor Blockers (ARBs) in Patients at High Risk of Cardiovascular Events: A Meta-Analysis of 10 Randomised Placebo-Controlled Trials
por: Ong, Hean Teik, et al.
Publicado: (2013)

Preventive use of beta-blockers for anthracycline-induced cardiotoxicity: A network meta-analysis
por: He, Dongsheng, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_n8tln6s3jadmp90p9vidu0vsd0